,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-07-02 03:24:00,You can probably tick off reasons why not to buy Veeva Systems (NYSE: VEEV) stock without trying very hard.,0.05622677132487297,0.013105579651892185,0.9306676387786865,neutral,0.04312119260430336
1,2017-07-02 03:24:00,Some might say that the stock is bound to run out of steam after racking up gains of more than 50% so far in 2017.,0.12761232256889343,0.8286558985710144,0.043731775134801865,negative,-0.7010436058044434
2,2017-07-02 03:24:00,More could predict that gaining new customers in the life sciences industry will be more challenging in the days ahead than they've been in the past.,0.4812854528427124,0.05276217684149742,0.46595239639282227,positive,0.4285232722759247
3,2017-07-02 03:24:00,Others could argue that Veeva's valuation is too pricey.,0.03198891878128052,0.6697738766670227,0.29823723435401917,negative,-0.6377849578857422
4,2017-07-02 03:24:00,None of these arguments aren't without some merit.,0.06495784223079681,0.028971713036298752,0.9060704708099365,neutral,0.03598612919449806
5,2017-07-02 03:24:00,"However, I think investors can still buy Veeva Systems stock and win over the long run.",0.8922094702720642,0.0145735964179039,0.09321688115596771,positive,0.8776358962059021
6,2017-07-02 03:24:00,Here are three reasons why.,0.011740867048501968,0.02663036249577999,0.961628794670105,neutral,-0.014889495447278023
7,2017-07-02 03:24:00,1.,0.029014499858021736,0.015284966677427292,0.9557005167007446,neutral,0.013729533180594444
8,2017-07-02 03:24:00,"Still a lot of opportunity in its core market

Veeva Systems has made tremendous in-roads in winning customers in the global life sciences industry.",0.9313505291938782,0.015375976450741291,0.05327349528670311,positive,0.9159745573997498
9,2017-07-02 03:24:00,"However, significant opportunities remain for expansion in this core market.",0.7724491953849792,0.011954083107411861,0.2155967503786087,positive,0.760495126247406
10,2017-07-02 03:24:00,"As of Jan. 31, 2017, Veeva claimed 517 customers.",0.014751618728041649,0.009957599453628063,0.975290834903717,neutral,0.004794019274413586
11,2017-07-02 03:24:00,"According to professional services firm Jones Lang Lasalle (NYSE: JLL) , there were over 20,000 life sciences establishments in the U.S. alone in 2014.",0.04175958037376404,0.012373125180602074,0.9458673596382141,neutral,0.029386455193161964
12,2017-07-02 03:24:00,"While not all of these would necessarily be target customers for Veeva, many of them would be, as would a lot more in other countries.",0.03408956900238991,0.007100469898432493,0.9588099122047424,neutral,0.026989098638296127
13,2017-07-02 03:24:00,A recent industry survey conducted by Veeva found that 99% of clinical operations professionals see a need to unify their clinical applications.,0.36034950613975525,0.019603261724114418,0.6200472712516785,neutral,0.3407462537288666
14,2017-07-02 03:24:00,Deloitte's 2017 global life sciences outlook report stated that the top action life sciences companies want to take to improve their business is to streamline processes.,0.7123358249664307,0.011520080268383026,0.2761440575122833,positive,0.700815737247467
15,2017-07-02 03:24:00,Both of these findings suggest that Veeva still has plenty of hay to make in its primary life sciences market.,0.7023245692253113,0.014509155414998531,0.2831663191318512,positive,0.6878154277801514
16,2017-07-02 03:24:00,2.,0.020992202684283257,0.01708322763442993,0.9619246125221252,neutral,0.003908975049853325
17,2017-07-02 03:24:00,"Even more possibilities in other markets

While Veeva Systems continues to expand in its core market, the company is also taking steps to venture into other markets.",0.8293105363845825,0.011721800081431866,0.15896761417388916,positive,0.817588746547699
18,2017-07-02 03:24:00,"Last year, Veeva stated its intention to grow beyond life sciences.",0.5447712540626526,0.008667395450174809,0.44656136631965637,positive,0.5361038446426392
19,2017-07-02 03:24:00,"In May, the company announced the first fruit from that effort by winning a contract with a top-five consumer packaged goods company.",0.9260227084159851,0.019446415826678276,0.05453091487288475,positive,0.9065762758255005
20,2017-07-02 03:24:00,Veeva's customer relationship management (CRM) software is built on the Salesforce.com (NYSE: CRM) platform.,0.022137511521577835,0.006591978017240763,0.9712705016136169,neutral,0.01554553396999836
21,2017-07-02 03:24:00,The company's agreement with Salesforce limits Veeva to only targeting biopharmaceutical companies.,0.026185328140854836,0.011366911232471466,0.9624477624893188,neutral,0.01481841690838337
22,2017-07-02 03:24:00,That restriction could certainly limit Veeva's growth into new markets if the company remains tied to the Salesforce platform.,0.03949064016342163,0.7137504816055298,0.2467588484287262,negative,-0.6742598414421082
23,2017-07-02 03:24:00,"However, Veeva's Vault products aren't CRM applications developed using Salesforce's platform.",0.010185993276536465,0.011860610917210579,0.977953314781189,neutral,-0.0016746176406741142
24,2017-07-02 03:24:00,This opens the door for the company to compete in other industries -- and even go head-to-head with Salesforce.,0.9374580383300781,0.017120754346251488,0.04542119801044464,positive,0.9203372597694397
25,2017-07-02 03:24:00,The first two reasons why Veeva could go higher address concerns about how the company can keep growing revenue and earnings.,0.6234323978424072,0.02549155056476593,0.3510761260986328,positive,0.5979408621788025
26,2017-07-02 03:24:00,"However, they don't necessarily do anything to alleviate concerns about Veeva's premium valuation.",0.2737440764904022,0.03616444393992424,0.6900914311408997,neutral,0.23757962882518768
27,2017-07-02 03:24:00,Shares currently trade at at whopping 62 times expected earnings.,0.09472309052944183,0.009115645661950111,0.8961612582206726,neutral,0.08560744673013687
28,2017-07-02 03:24:00,"I would argue, though, that Veeva's current valuation probably won't be a barrier to the stock going higher.",0.07679188251495361,0.029424745589494705,0.8937833309173584,neutral,0.04736713692545891
29,2017-07-02 03:24:00,Look at Salesforce as a good case study.,0.09005125612020493,0.00809434149414301,0.9018544554710388,neutral,0.08195691555738449
30,2017-07-02 03:24:00,Its earnings multiple has been much higher than Veeva's forward earnings multiple for practically the entire time that the stock has traded.,0.8778091669082642,0.03199600800871849,0.09019485116004944,positive,0.8458131551742554
31,2017-07-02 03:24:00,Veeva in several respects is like Salesforce in its earlier years.,0.11167164891958237,0.007871958427131176,0.8804563879966736,neutral,0.10379969328641891
32,2017-07-02 03:24:00,"Also, there's a great dynamic at work for Veeva that could help its valuation become less scary in the future.",0.8583544492721558,0.013913771137595177,0.12773172557353973,positive,0.8444406986236572
33,2017-07-02 03:24:00,"As the company gets more customer on its cloud-based applications, its profitability should increase.",0.9563259482383728,0.0162101648747921,0.02746390365064144,positive,0.9401158094406128
34,2017-07-02 03:24:00,Note that Veeva's costs as a percentage of revenue for its subscription services are decreasing.,0.06332864612340927,0.8386386632919312,0.09803276509046555,negative,-0.7753100395202637
35,2017-07-02 03:24:00,That trend should continue.,0.6563606858253479,0.011687226593494415,0.33195212483406067,positive,0.6446734666824341
36,2017-07-02 03:24:00,There are certainly risks to buying Veeva Systems stock.,0.05304962396621704,0.10915932804346085,0.8377910852432251,neutral,-0.056109704077243805
37,2017-07-02 03:24:00,The company could face a steeper challenge in gaining market share in other industries than it expects.,0.8716313242912292,0.029459228739142418,0.09890938550233841,positive,0.8421720862388611
38,2017-07-02 03:24:00,"While Salesforce can't compete against Veeva in the life sciences market per the two companies' agreement, that doesn't mean that others can't or won't.",0.05440696328878403,0.1926807314157486,0.7529123425483704,neutral,-0.13827377557754517
39,2017-07-02 03:24:00,Any bump in the road could take a major toll on Veeva's share price.,0.0270448699593544,0.9403456449508667,0.0326094776391983,negative,-0.9133007526397705
40,2017-07-02 03:24:00,That's to be expected with a stock trading at a high valuation.,0.19451026618480682,0.01888299733400345,0.7866066694259644,neutral,0.17562726140022278
41,2017-07-02 03:24:00,"Still, I fully expect Veeva Systems to continue growing like crazy.",0.6570178270339966,0.009335470385849476,0.3336467146873474,positive,0.6476823687553406
42,2017-07-02 03:24:00,I think it will maintain its dominance in the life sciences market and successfully edge into new markets over time.,0.9229448437690735,0.012445284053683281,0.06460980325937271,positive,0.9104995727539062
43,2017-07-02 03:24:00,"In my view, the potential rewards with Veeva outweigh the risks.",0.3138900697231293,0.012886876240372658,0.673223078250885,neutral,0.30100318789482117
44,2017-07-02 03:24:00,"10 stocks we like better than Veeva Systems

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12699975073337555,0.025114860385656357,0.8478853702545166,neutral,0.1018848866224289
45,2017-07-02 03:24:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
46,2017-07-02 03:24:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Veeva Systems wasn't one of them!",0.2355690747499466,0.014962825924158096,0.7494681477546692,neutral,0.2206062525510788
47,2017-07-02 03:24:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
48,2017-07-02 03:24:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
49,2017-07-02 03:24:00,Keith Speights has no position in any stocks mentioned.,0.009554922580718994,0.03749576956033707,0.9529493451118469,neutral,-0.027940846979618073
50,2017-07-02 03:24:00,The Motley Fool owns shares of and recommends Veeva Systems.,0.034477271139621735,0.013045232743024826,0.9524774551391602,neutral,0.02143203839659691
51,2017-07-02 03:24:00,The Motley Fool recommends Jones Lang LaSalle and Salesforce.com.,0.016537249088287354,0.021578194573521614,0.961884617805481,neutral,-0.0050409454852342606
52,2017-07-02 03:24:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
53,2017-07-02 03:24:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
